Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2023-04-05 00:00:00 ET · period of report 2023-04-03 · accession 0001415889-23-006321 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-04-05 | 2023-04-03 | JBIO | NOYES TIMOTHY P | CEO, Dir | S - Sale+OE | $19.40 | -15.0K | 5,828 | -72% | -$291.0K |
| D | 2023-04-05 | 2023-04-03 | JBIO | NOYES TIMOTHY P | CEO, Dir | M - OptEx | $2.14 | +15.0K | 15.0K | New | +$32.1K |
| D | 2023-04-05 | 2023-04-03 | JBIO | NOYES TIMOTHY P | CEO, Dir | M - OptEx | $0.00 | -15.0K | 418.4K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-03 | S | D | 5,828 | $19.77 | 0 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.51 to $20.22, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2023-04-03 | M | A | 15,000 | $2.14 | 15,000 | D | — | — | |
| 3 | Common | Common Stock | 2023-04-03 | S | D | 9,172 | $19.16 | 5,828 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.50 to $19.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-04-03 | M | D | 15,000 | $0.00 | 418,381 | D | $2.14 · — to 2031-04-01 | 15,000 Common Stock | (F4) A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. |